Any studies compare the efficacy among ACE Inhibitors?

Question

Please give me details or web links.

Answer 1

Summarizing the Evidence


Captopril, enalapril, lisinopril, ramipril and trandolapril have been studied in clinical trials and have been shown to reduce the rate of death and hospitalizations in individuals who have had a heart attack.

The American College of Cardiology and American Heart Association (ACC/AHA) guidelines for treatment of a heart attack recommend that heart attack patients with decreased heart function, especially patients with diabetes, should receive an ACE Inhibitor because they are at high risk for developing congestive heart failure. No specific ACE Inhibitor is recommended, although experience is the greatest with captopril, lisinopril, ramipril, and trandolapril. A recent trial showed that ramipril reduced the numbers of heart attacks, strokes, and heart death in patients with established heart or vessel disease, and/or diabetes.

Limited data is available for benazepril, fosinopril, moexipril, quinapril and perindopril when used following a heart attack.

Although not well studied and proven, because the drugs work the same way, it is generally believed that they should be similar in effectiveness in treating and preventing a heart attack.

Common side effects of the ACE Inhibitors include nausea, vomiting and diarrhea, cough, low blood pressure, headache and dizziness. A dry non-productive cough is the most frequently reported side effect with this drug class. While it appears as though the incidence of cough is similar amongst all ACE Inhibitors, some patients who experience a cough while taking one ACE Inhibitor will not necessarily experience a cough when they switch to another ACE Inhibitor. A few studies have demonstrated that patients taking fosinopril may have the least incidence of cough. If your cough becomes bothersome, you should contact your doctor.

sencond link--excellant also

ACE inhibitors: key points

For hypertension and heart failure, benefits are likely to be class effects, and there are no primary reasons for preferring individual drugs

For newer indications, in which only one drug has been tested, efficacy is probably a class effect but equal safety cannot be assumed

For these newer indications, the trial drugs, ramipril and perindopril, should be used unless greater cost reduces the number of patients who can be treated by more than the possible increase in safety